Sarepta Therapeutics (SRPT) Finished Goods (2016 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Finished Goods of $58.0 million for Q1 2026, down 5.54% year-over-year from $61.4 million in Q1 2025, and down 11.24% quarter-over-quarter from $65.3 million in Q4 2025.
Sarepta Therapeutics (SRPT) Finished Goods (2016 - 2026) Analysis & Trends
Sarepta Therapeutics' Finished Goods history runs 11 years deep, the most recent figure standing at $58.0 million for Q1 2026.
- In Q1 2026, Finished Goods fell 5.54% year-over-year to $58.0 million; the TTM figure through Mar 2026 stood at $58.0 million (down 5.54% YoY), while the FY2025 annual figure was $65.3 million, up 38.36% from the prior year.
- Finished Goods for Q1 2026 stood at $58.0 million, down from $65.3 million in the prior quarter.
- The five-year high for Finished Goods was $78.0 million in Q3 2024, with the low at $33.9 million in Q1 2022.
- The 5-year median for Finished Goods is $49.3 million (2022), against an average of $52.6 million.
- The sharpest annual moves came in 2022 and 2024: Finished Goods surged 83.58% in 2022, then slipped 23.62% in 2024.
- Sarepta Therapeutics' Finished Goods stood at $38.1 million in 2022, then jumped by 62.02% to $61.8 million in 2023, then retreated by 23.62% to $47.2 million in 2024, then surged by 38.36% to $65.3 million in 2025, then fell by 11.24% to $58.0 million in 2026.
- Business Quant data shows SRPT's Finished Goods at $58.0 million in Q1 2026, $65.3 million in Q4 2025, and $64.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.18 Mn |
| Mar 31, 2026 | 57.98 Mn |
| Dec 31, 2025 | 65.32 Mn |
| Sep 30, 2025 | 64.80 Mn |
| Jun 30, 2025 | 70.98 Mn |
| Mar 31, 2025 | 61.37 Mn |
| Dec 31, 2024 | 47.21 Mn |
| Sep 30, 2024 | 77.98 Mn |
| Jun 30, 2024 | 52.90 Mn |
| Mar 31, 2024 | 39.50 Mn |
| Dec 31, 2023 | 61.81 Mn |
| Sep 30, 2023 | 47.24 Mn |
| Jun 30, 2023 | 47.61 Mn |
| Mar 31, 2023 | 42.69 Mn |
| Dec 31, 2022 | 38.15 Mn |
| Sep 30, 2022 | 49.26 Mn |
| Jun 30, 2022 | 35.50 Mn |
| Mar 31, 2022 | 33.88 Mn |
| Dec 31, 2021 | 26.72 Mn |
| Sep 30, 2021 | 26.83 Mn |